Patents by Inventor Luc Montagnier

Luc Montagnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020086285
    Abstract: A variant of a LAV virus, designated LAVELI and capable of causing AIDS. The cDNA and antigens of the LAVELI virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: November 13, 2001
    Publication date: July 4, 2002
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Publication number: 20020076691
    Abstract: A variant of a LAV virus, designated LAVELI and capable of causing AIDS. The cDNA and antigens of the LAVELI virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: January 23, 2001
    Publication date: June 20, 2002
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 6399294
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: June 4, 2002
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques Cohen
  • Patent number: 6395495
    Abstract: The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: May 28, 2002
    Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Robert C Gallo, Mikulas Popovic, Mangalasseril G Sarngadhar, Claudine Axler-Blin, Solange Chamaret
  • Publication number: 20020051967
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.
    Type: Application
    Filed: May 23, 2001
    Publication date: May 2, 2002
    Applicant: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Patent number: 6355789
    Abstract: The present invention is directed toward nucleic acids containing the full-length human immunodeficiency virus type 2 ROD (HIV-2ROD) pol gene. HIV-2, which was originally designated lymphadenopathy-associated virus type II (LAV-II), was isolated from AIDS patients in West Africa. The virus is genotypically and phenotypically distinct from HIV-1 and bears a closer genetic relationship to the simian immunodeficiency virus (SIV). The present invention describes the preparation of HIV-2ROD proviral molecular clones from a genomic lambda phage library of CD4+-infected cells. The complete nucleotide sequence of the full-length genome was determined and the putative gag, pol, env, vif (Q), vpr (R), vpx (X), nef (F), tat, and rev (art) genes identified. The claimed invention is directed toward nucleic acids containing the full-length HIV-2ROD pol gene (nt 1829-4936). These nucleic acids should prove useful as diagnostic reagents for the detection of HIV-2 and facilitate expression of the pol gene product.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 12, 2002
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Publication number: 20020022033
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: April 16, 2001
    Publication date: February 21, 2002
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 6337179
    Abstract: Methods and kits for the in vitro detection of antibodies of an HIV variant are disclosed. In particular, the detection of HIV-1 variants, such as LAVBRU, LAVELI, LAVMAL, are taught by using an immunologically distinct antigen of these HIV variants to detect the antibodies of these variants. Moreover, the immunological characteristics of the HIV-1 variants of the invention are disclosed.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: January 8, 2002
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 6322964
    Abstract: Peptide sequences are disclosed which immunologically mimic proteins encoded by the env and gag regions of LAV-2, a retrovirus associated with AIDS. The peptide can be used in various specific binding assays to detect the presence of antibodies to LAV-2 in individuals previously exposed to the virus. The peptides enable one to distinguish the presence of antibodies to LAV-2 from antibodies to HIV-1.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: November 27, 2001
    Assignees: Genetic Systems Corporation, Institut Pasteur
    Inventors: Wesley L. Cosand, Andrew J. Watson, Raymond L. Houghton, Luc Montagnier, Marc Alizon, Solange Chamaret
  • Patent number: 6316183
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 13, 2001
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 6296807
    Abstract: The invention relates to a novel retrovirus isolated from patients in West Africa that is capable of causing lymphadenopathies and the acquired immune deficiency syndrome (AIDS). This virus, which was originally designated “LAV type II”, “LAV-II”, or “West African AIDS retrovirus”, has been subsequently renamed the human immunodeficiency virus type 2 (HIV-2). Two isolates were obtained, characterized, and designated HIV-2MIR and HIV-2ROD (C.N.C.M. deposit nos. I-502 and I-532, respectively). Radioimmunoprecipitation (RIPA) and Western blot analyses involving patient antisera identified viral proteins with molecular weights of 16 Kd (p16), 26 Kd (p26), 130-140 Kd (gp130-140), and 36 Kd (gp36). The claimed invention is directed toward kits for the detection of HIV-2 antigens comprising polyclonal and monoclonal antisera directed against these proteins.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: October 2, 2001
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 6284454
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: September 4, 2001
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 6265149
    Abstract: The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 24, 2001
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Patent number: 6261571
    Abstract: The invention relates to an isolated immune complex comprising a protein and an antibody that binds with said protein, wherein the protein is selected from the group consisting of gp80 of HIV-2 and gp65 of SIV, wherein said gp80 is a glycoprotein having an apparent molecular weight of 80 kDa, as determined by SDS-PAGE, and further wherein said gp65 is a glycoprotein having an apparent molecular weight of 65 kDa as determined by SDS-PAGE. Also provided are an immunogenic composition comprising an amount of gp80 protein of human immunodeficiency virus type 2 (HIV-2) sufficient to induce an immune response and a pharmaceutically acceptible carrier, and a composition comprising at least one antigen selected from the group consisting of gp80 protein of HIV-2 and gp65SIV.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: July 17, 2001
    Assignee: Institute Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 6261762
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: January 2, 1997
    Date of Patent: July 17, 2001
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Duetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Publication number: 20010006641
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp14O, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Application
    Filed: December 19, 2000
    Publication date: July 5, 2001
    Applicant: Institut Pasteur
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuille
  • Patent number: 6197496
    Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2 are disclosed. Particularly, the HIV-2 proteins, gp300, p200, p90, and p80, and gp300 of SIV are described.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: March 6, 2001
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Anne G. Laurent Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuillé
  • Patent number: 6194142
    Abstract: The present invention relates to polypeptides encoded by a nucleotide sequence from an HIV-1, HIV-2, or SIV viral genome, in which the nucleotide sequence is amplified from the viral genome using a pair of primers that contain sequences that are conserved between different HIV and SIV strains. The primers are insensitive to variations in the genomes of different HIV and SIV isolates and, therefore, can be used to amplify nucleotide sequences from HIV-1, HIV-2, and SIV strains. The invention also relates to antibodies directed against these polypeptides and methods and kits for diagnosing viral infection.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: February 27, 2001
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier
  • Patent number: 6162439
    Abstract: This invention is directed toward polypeptides derived from novel lentiviruses. A novel lentivirus, designated the human immunodeficiency virus type 2, was isolated from West African patients with acquired immune deficiency syndrome (AIDS). Several isolates were obtained and designated HIV-2.sub.ROD, HIV-2.sub.IRMO, and HIV-2.sub.EHO. A recombinant lambda phage library was constructed from HIV-2.sub.ROD -infected CEM genomic DNA. Overlapping molecular clones were obtained and the nucleotide sequence of the complete 9.5-kilobase (kb) HIV-2.sub.ROD genome ascertained. The genetic organization of HIV-2 is analogous to that of other retroviruses and consists of the 5'LTR-gag-pol-central region-env-nef-3'LTR. The central region also encodes for the regulatory proteins Tat and Rev, as well as the ancillary proteins Vif, Vpr, and Vpx. The proteins encoded by this proviral clone will provide novel immunologic, biochemic, and diagnostic reagents useful for the detection of HIV-2.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 19, 2000
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6056963
    Abstract: This invention is directed to a composition comprising one or more human immunodeficiency virus type 2 (HIV-2) envelope proteins and a pharmaceutically acceptable carrier. The proteins of the claimed invention are gp300, p200 and p90/80 of HIV-2. The composition is useful for the diagnostic assay of HIV-2 and as an antigen for the production of antibodies, for example.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 2, 2000
    Assignee: Institut Pasteur and Centre Nationale de la Recherche Scientifique (C.N.R.S.)
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuille